Sprint Bioscience

26/06/2025

Sprint Bioscience is proud to announce that groundbreaking results from our DCPS program have been published in Leukemia, a leading journal in hematology and oncology from Nature. 📖 https://doi.org/10.1038/s41375-025-02661-z
The article highlights DCPS as a promising therapeutic target in Acute Myeloid Leukemia (AML). These findings pave the way for more precise patient selection and improved treatment outcomes, while maintaining a favorable safety profile.

This publication is the result of a strong collaboration with Karolinska Institutet, NeoTargets AB Julian Walfridsson, BioReperia, and support from the Swedish Foundation for Strategic Research: Stiftelsen för strategisk forskning, SSF has partially funded it through an industrial PhD fellowship.
A great step forward in our quest to make a difference for those affected by cancers such as AML.

Press release ➡️https://sprintbioscience.com/en/press-release/?slug=sprint-biosciences-dcps-data-published-in-leukemia
Sprint Bioscience team📸

25/06/2025

We’re proud to share a highlight of Vladimir Talibov, Associate Principal Scientist, Protein Science, Sprint Bioscience, who had the possibility to attend and present at Discovery & Development Europe 2025 summit in Basel ➡️ https://oxfordglobal.com/discovery-development/events/discovery-development-europe.

As part of the Hit Identification & Screening track, Vladimir delivered a compelling presentation titled ▪️“Leveraging Coupled Equilibrium in Fragment Screening”.

This talk explored innovative strategies in fragment-based drug discovery, emphasizing how coupled equilibrium can enhance screening efficiency and lead to more robust hit identification — a critical step in early-stage drug development.

A big thank you to the organizers at Oxford Global Conferences for creating a platform for knowledge exchange and innovation in biopharma R&D.

19/06/2025

Sprint Bioscience is proud to announce a research collaboration with the Experimental Drug Development Centre (EDDC) in Singapore regarding the therapeutic expansion of one of our programmes into inflammatory diseases.

“We are very pleased that our programme is attracting interest in inflammatory conditions as well, and excited at the potential to help patients with various inflammatory and autoimmune diseases. Given Sprint Bioscience’s focus on oncology, we see this collaboration as an excellent opportunity to gain access to the expertise required to evaluate these opportunities, thereby maximising the value of the programme,” says Johan Emilsson, CEO of Sprint Bioscience.

Full press release with more information about EDDC and the collaboration ➡️ https://sprintbioscience.com/en/press-release/?slug=sprint-bioscience-collaborates-to-expand-its-mash-programme-into-inflammation

This collaboration reflects our commitment to advancing innovative science and addressing unmet medical needs through strategic global partnerships.

17/06/2025

Sprint Bioscience is proud to be represented at . As always, one-to-one meetings and high-energy networking are keeping our leadership trio 📸 CEO Johan Emilsson, CBO Anne-Marie Wenthzel, and CSO Martin Andersson, busy. The first days of the convention have already shown the power of collaboration in biotech – and we’re here to connect with partners who share our vision for advancing science to deliver tangible benefits for patients. We are pleased to engage with both longstanding colleagues and new connections within the global biotech community.
Biotechnology Innovation Organization has organized an outstanding convention!

12/06/2025

The Sprint Bioscience team with, Johan Emilsson Anne-Marie Wenthzel Martin Andersson, are ready to meet you at in Boston next week.
As the world’s largest biotech gathering, BIO International Convention brings together 20,000 global leaders to shape the future of healthcare. It’s where innovation meets opportunity — and where we’ll be ready to connect.
The schedule is almost filled, but there’s still time to request a meeting through the partnering system ➡️ https://partner.bio.org/conference/68/search?keyword=Sprint&searchedTile=companies&sortBy=relevancy
Let’s explore new possibilities in oncology and drug development together.

04/06/2025

At Sprint Bioscience, we’re proud to collaborate with SciLifeLab and the SciLifeLab Drug Discovery & Development (DDD) Platform to enhance the speed and precision of our fragment-based drug discovery efforts. By leveraging SciLifeLab’s intact mass analysis capabilities, we gain rapid and reliable verification of protein batch identity—an essential step in our workflow.

“When we need to confirm that a newly purified protein batch is correct and consistent, we can’t afford to wait. That’s where SciLifeLab has been invaluable,” — Camilla Silvander, Director of Protein Science, Sprint Bioscience

This collaboration has also helped SciLifeLab expand its services:

“Sprint Bioscience played a key role in confirming the demand for intact mass determination in drug discovery workflows,” — Pawel Baranczewski, Head of the ADME of Therapeutics Unit, DDD Platform

Discover the full story at SciLifeLab's website ➡️ https://www.scilifelab.se/news/industry-case-sprint-bioscience-uses-scilifelab-infrastructure-to-accelerate-early-cancer-drug-development/

With a focus on speed, precision, and early innovation, Sprint Bioscience is developing small-molecule therapies for cancer. By partnering with SciLifeLab’s Drug Discovery and Development (DDD) Platform, the Stockholm-based biotech […]

09/05/2025

Sprint Bioscience has announced the outcome of the Rights Issue, which will provide the company with approximately SEK 23.4 million before costs. The issue was subscribed to approximately 74 percent, of which about 41 percent was subscribed with subscription rights, just under 2 percent without subscription rights, and the remaining 31 percent was allocated to the guarantors. Sprint Bioscience’s largest shareholder First Venture https://www.first-venture.se/ increased its participation compared to previous communication and subscribed for shares corresponding to SEK 4.3 million (SEK 3.0 million).

We welcome Life Science Invest Fund https://www.lsif.dk/, as a new owner. Through their participation as a guarantor, LSIF is now one of the company's five largest shareholders.

We would like to thank everyone who contributed to the issue. Together, we look forward – thank you for your continued trust!

In connection with the issue, Sprint Bioscience has engaged Sedermera Corporate Finance as financial advisor Fredersen Advokatbyrå as legal advisor and Nordic Issuing as issuing agent.

All information regarding the right issue is available on our website: https://sprintbioscience.com/sv/foretradesemission/foretradesemission-2025/

24/04/2025

Sprint Bioscience proudly opened the Lilla Lördag breakfast seminar series, where you can listen to presentations from life science companies, meet fellow peers, and enjoy a delicious breakfast – every Wednesday here at Novum Forskarpark at Hälsovägen 7 – the Life Science Cluster Flemingsberg.

Martin Andersson, co-founder and Chief Scientific Officer, shared the story of how the company was founded, the ups and downs of starting a company, and what we do daily in our labs. It was great to see such a turnout! Don’t miss the upcoming events from our fellow neighbors and cluster community: 🗓️ https://flemingsbergscience.se/sv/aktuellt/pa-gang/ by Flemingsberg Science

16/04/2025

Earlier this week, Sprint Bioscience participated in an investor meeting hosted by Financial Stockholm. This time, our Chief Scientific Officer, Martin Andersson, delivered a presentation about the company, our business model, partnership strategy, and the future steps for Sprint Bioscience.
See the presentation (in Swedish) here: https://sprintbioscience.com/sv/film/sprint-biosciences-cso-martin-andersson-presenterar-bolaget/

15/04/2025

Last week, Sprint Bioscience’s Martin Andersson and Niklas Axelsson attended the Stockholms Chamber of Commerce's, report launch on the Life Science sector in the Stockholm-Uppsala region, titled "From Nobel Prize to Business – How We Become the Best at Turning Research into Success." The report highlights Flemingsberg's significant role in the development of Life Science in the Stockholm-Uppsala area and we are very proud to be mentioned together with some our neighbors: 🧪AlzeCure Pharma, NextCell Pharma, Circio & Smartcella. 🧫

We extend our gratitude to the Stockholms Handelskammare - Stockholm Chamber of Commerce, for this important report and to Stiftelsen Flemingsberg Science for their continuous efforts to promote and strengthen our area. Read the full report here 🔎 https://stockholmshandelskammare.se/rapporter/fran-nobelpris-till-naringsliv/

14/04/2025

CEO Johan Emilsson visited BioStock’s studio and shared insights into our business model, partnership strategy, and the exciting next steps for Sprint Bioscience. Discover how we take small molecule pre-clinical programs from ideas to global collaboration and what makes our strategy unique. Watch the video here: https://sprintbioscience.com/sv/film/intervju-med-sprint-biosciences-vd-johan-emilsson/
Watch the company presentation: https://sprintbioscience.com/sv/film/sprint-biosciences-vd-johan-emilsson-presenterar-bolaget/
BioStock - Connecting Innovation & Capital

09/04/2025

As of yesterday, the subscription period for Sprint Bioscience’s rights issue has begun. Read BioStock's interview (in Swedish) with CEO Johan Emilsson about the ongoing rights issue. https://www.biostock.se/2025/04/sprint-biosciences-vd-om-nyemission-och-affarsutveckling/
The subscription rights are being traded on the First North Premier Growth Market until April 17, 2025, and the subscription period will continue until April 24, 2025. Information can be found on our website: https://sprintbioscience.com/sv/foretradesemission/foretradesemission-2025/

Ett licensavtal är i hamn och fler ska det bli. I alla fall om man får tro Sprint Biosciences vd Johan Emilsson. BioStock har kontaktat honom.